Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd.

November 10, 2011 13:12 ET

VentriPoint Diagnostics Investor Presentation Now Available Online

CALGARY, ALBERTA--(Marketwire - Nov. 10, 2011) -

Editor's Note: There is a photo and a video associated with this release.

On October 24, 2011 The Howard Group hosted its 3rd annual "Opportunity Knocks" investor conference in Calgary. Dr. George Adams, President & CEO of VentriPoint (TSX VENTURE:VPT) provided an overview of the company to an audience of investment advisors & private investors.

A recording of the presentation is now available online. Click here to view -

Highlights on VentriPoint are as follows:

  • VentriPoint's VMS™ 3D technology monitors patients with heart disease.
  • Management has exceeded expectations on business plan, which included installations, sales, capital raised.
  • Sales ramping up. The company expects to move into positive cash flow in 2012.
  • Multibillion Dollar markets includes patients with Pulmonary Hypertension.
  • Expect FDA approval in the Spring of 2012.
  • Company expects to develop a strategic relationship in the near future.

About VentriPoint Diagnostics Ltd:

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Monitoring congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there by any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

To view the fact sheet associated with this release, please see the following link:

To view the photo associated with this release, please see the following link:

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Ventripoint Diagnostics
    George Adams
    President & CEO
    (206) 283-0221
    (206) 283-2309 (FAX)

    The Howard Group Inc.
    Peter Weichler
    Investor Relations
    (403) 221-0915 or Toll Free: 1-888-221-0915

    The Howard Group Inc.
    Dave Burwell
    Investor Relations
    (403) 221-0915 or Toll Free: 1-888-221-0915


Keyword Cloud

View Website